Profile data is unavailable for this security.
About the company
Kanabo Group plc is a United Kingdom-based patient-focused provider of digital health services and specialist medicines, including medicinal cannabis. The Company’s principal activities are the distribution and development of cannabis derived medical and wellness products. The Company is focused on the distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for cannabidiol (CBD) consumers. It has conducted research and development (R&D) in order to develop cannabis extract formulas, medical-grade vaporizers and various non-smoking consumption solutions. Its clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The Company operates through two segments: Primary case and Secondary case. Primary case segment is involved in the telepharma services provided by GPS. Secondary case segment is involved in the distribution and development of cannabis-derived medical and wellness products.
- Revenue in GBP (TTM)895.00k
- Net income in GBP-7.99m
- Incorporated2016
- Employees20.00
- LocationKanabo Group PLCChurchill House, 137-139 Brent StreetLONDON NW4 4DJUnited KingdomGBR
- Websitehttps://www.kanabogroup.com/investors/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| BSF Enterprise PLC | 67.24k | -1.71m |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m |
| Synairgen plc | 0.00 | -8.41m |
| Oncimmune Holdings PLC | 1.21m | -3.19m |
| ImmuPharma PLC | 0.00 | -2.92m |
| Kanabo Group PLC | 895.00k | -7.99m |
| Genflow Biosciences PLC | 0.00 | -1.63m |
| Destiny Pharma PLC | 0.00 | -5.66m |
| Bivictrix Therapeutics PLC | 0.00 | -2.55m |
| Chill Brands Group PLC | 146.62k | -3.64m |
| Genincode PLC | 2.16m | -7.02m |
| Proteome Sciences plc | 5.03m | -2.44m |
| Abingdon Health PLC | 5.34m | -2.24m |
| Provexis plc | 598.08k | -496.59k |
